UNCY Unicycive Therapeutics Inc
Price (delayed)
$0.5485
Market cap
$65.66M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.56
Enterprise value
$40.2M
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic
Highlights
The company's EPS has surged by 56% YoY and by 24% QoQ
UNCY's debt is down by 16% since the previous quarter and by 14% year-on-year
UNCY's quick ratio has soared by 96% year-on-year but it has dropped by 65% since the previous quarter
The equity has dropped by 73% since the previous quarter
UNCY's net income has dropped by 60% since the previous quarter and by 20% year-on-year
Key stats
What are the main financial stats of UNCY
Market
Valuations
Earnings
Shares outstanding
119.71M
Market cap
$65.66M
Enterprise value
$40.2M
Price to earnings (P/E)
N/A
Price to book (P/B)
7.66
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$32.12M
Net income
-$36.73M
EBIT
-$36.66M
EBITDA
-$36.23M
Free cash flow
-$28.65M
Per share
Balance sheet
Liquidity
EPS
-$0.56
EPS diluted
-$0.56
Free cash flow per share
-$0.43
Book value per share
$0.07
Revenue per share
$0
TBVPS
$0.47
Total assets
$31.67M
Total liabilities
$24.24M
Debt
$681,000
Equity
$7.43M
Working capital
$6.83M
Debt to equity
0.09
Current ratio
1.28
Quick ratio
1.08
Net debt/EBITDA
0.7
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-90.4%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-485.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
UNCY stock price
How has the Unicycive Therapeutics stock price performed over time
Intraday
0.46%
1 week
-11.36%
1 month
-0.33%
1 year
-60.25%
YTD
-30.94%
QTD
-4.59%
Financial performance
How have Unicycive Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$32.12M
Net income
-$36.73M
Gross margin
N/A
Net margin
N/A
UNCY's net income has dropped by 60% since the previous quarter and by 20% year-on-year
The company's operating income fell by 50% YoY and by 10% QoQ
Growth
What is Unicycive Therapeutics's growth rate over time
Valuation
What is Unicycive Therapeutics stock price valuation
P/E
N/A
P/B
7.66
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 56% YoY and by 24% QoQ
The equity has dropped by 73% since the previous quarter
Efficiency
How efficient is Unicycive Therapeutics business performance
UNCY's ROA is up by 40% YoY but it is down by 13% QoQ
Dividends
What is UNCY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for UNCY.
Financial health
How did Unicycive Therapeutics financials performed over time
Unicycive Therapeutics's total assets is 31% more than its total liabilities
Unicycive Therapeutics's total liabilities has soared by 126% from the previous quarter and by 35% YoY
Unicycive Therapeutics's total assets has soared by 123% YoY but it has decreased by 18% from the previous quarter
UNCY's debt is 91% smaller than its equity
Unicycive Therapeutics's debt to equity has surged by 200% QoQ and by 143% YoY
The equity has dropped by 73% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.